Preliminary Agenda for virtual CROI, March 6-10, 2021

Program Committee Workshop for New Investigators and Trainees

This workshop describes the current state-of-the-art of selected areas of HIV and SARS-CoV-2 basic, epidemiologic, and clinical research being presented at CROI 2021. The workshop is directed toward new investigators (both international and domestic) and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows).

• Advances in Molecular Virology – Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany
• Advances in Immunology – Galit Alter, Ragon Institute of MGH, Cambridge, MA, USA
• Advances in HIV Prevention – Jean-Michel Molina, University of Paris, Paris, France
• Advances in HIV Cure – Katharine Bar, University of Pennsylvania, Philadelphia, PA, USA
• Advances in COVID-19 – Jürgen Rockstroh, Medizinische Universitatsklini, Bonn, Germany

Live Content Wrap-Up

Daily wrap-up of live content and a roadmap of on-demand content.

Welcome from the Program Committee Chairs

Welcome and Daily Roadmap

Martin Delaney Presentation

Panel Discussion on HIV and the COVID-19 Advocacy and Community Response

• Gregg Gonsalves, Yale University, New Haven, CT, USA
• Fatima Hassan, Health Justice Initiative, Cape Town, South Africa

Bernard Fields Lecture

Pamela Bjorkman, California Institute of Technology, Pasadena, CA, USA

N’Galy-Mann Lecture

Anthony S. Fauci, National Institutes of Health, Bethesda, MD, USA

Break

Concurrent Technical Workshops

Frontiers in Laboratory Sciences

1. Understanding Structures of SARS-CoV-2 Proteins and Neutralizing Antibodies – Christopher Barnes, California Institute of Technology, Pasadena, CA, USA
2. Emerging Concepts in HIV-1 Restriction – Edward Campbell, Loyola University Chicago, Chicago, IL, USA
3. Cross-Reactive T cells in COVID-19 and Other Coronavirus Infections – Daniela Weiskopf, La Jolla Institute for Immunology, La Jolla, CA, USA
4. Artificial Intelligence-Inspired Antibody-Engineering – Sai Reddy, Swiss Federal Institute of Technology, Zurich, Switzerland

Clinical Trial Design and Analysis

1. Platform Trials and Adaptive Trial Designs for COVID-19 – Lori Dodd, National Institutes of Health, Bethesda, MD, USA
2. Challenges in Designing and Implementing COVID-19 Vaccine Trials – Holly Janes, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Case-Based COVID-19 Clinical Workshop

1. COVID-19: Finding the Source of the Infection – Kwok-Yung Yuen, The University of Hong Kong, Hong Kong
2. COVID-19: A Patient Needing Oxygen but Not on a Ventilator – Sanjay Bhagani, Royal Free Hospital, London, United Kingdom
3. Critical Care of COVID-19 – Janhavi Athale, Johns Hopkins Hospital, Baltimore, MD, USA

Live Content Wrap-Up

Daily wrap-up of live content and a roadmap of on-demand content.

Opening

Welcome and Daily Roadmap

Plenary Presentations

Imaging Viral Life Cycles
Hans-Georg Kräusslich, Heidelberg University, Heidelberg, Germany

Disparities in Health: From HIV to COVID-19 and Beyond
James Hildreth, Meharry Medical College, Nashville, TN, USA

Break

Concurrent Oral Abstract Sessions

New abstract-driven research in HIV infection, other emerging viral infections such as hepatitis C virus, and SARS-CoV-2.

Break

Concurrent Interactive Sessions

Interactive and scientifically fun sessions in a mixture of lively formats such as debates, point-counterpoint discussions, brief talks with expert panel discussions, and “Rapid Fire” sessions: 4 or 5 short (5 mins) presentations by experts in the field.

SARS-CoV2 Evolution in Populations and Individuals

1. SARS-CoV-2 and HIV Evolution at the Population Level – Bette Korber, Los Alamos National Laboratory, Los Alamos, NM, USA
2. SARS-CoV-2 Evolution at the Population Level – Morgane Rolland, Walter Reed Army Institute of Research, Silver Spring, MD, USA
3. Viral and Antibody Evolution in Populations – Jeremy Luban, University of Massachusetts, Worcester, MA, USA
4. Variants to the SARS-CoV-2 Virus – TBD
5. Selection of Neutralization Resistant SARS-CoV-2 Mutants – Paul Bieniasz, The Rockefeller University, New York, NY, USA

Case-Based Discussion on Weight Gain in HIV and Antiretroviral Therapy

• Moderator: Peter Hunt, University of California San Francisco, San Francisco, CA, USA
• Panelists
  • Grace McComsey, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
  • Sadaf Farooqi, Cambridge University, Cambridge, United Kingdom
  • Jane O’Halloran, Washington University in St Louis, St Louis, MO, USA
  • Cissy Kityo, Joint Clinical Research Centre, Lubowa, Uganda

Contact Tracing in Controlling Epidemics: Is the Juice Worth the Squeeze?

• Moderator: Wafaa El-Sadr, Columbia University, New York, NY, USA
• Panelists
  • Matthew Golden, University of Washington, Seattle, WA, USA
  • Jeffrey Kahn, Johns Hopkins University, Baltimore, MD, USA

Live Content Wrap-Up

Daily wrap-up of live content and a roadmap of on-demand content.

Science Spotlights^™

Science Spotlights^™ are a new format for presenting important science that is not part of an oral abstract session. More details are available on the Science Spotlights^™ page

Symposia

Two-hour Symposia include 4 state-of-the-art talks. Symposia are scheduled on each day of CROI. Speakers are provided 20 to 23 minutes to present.

Navigating to the Nucleus

1. Live Cell Imaging: Capsid Trafficking to Nucleus – Barbara Müller, University of Heidelberg, Heidelberg, Germany
2. Single Virion Trafficking to Nucleus – Vinay Pathak, National Cancer Institute, Frederick, MD, USA
3. Imaging Capsid Dependent Reverse Transcription – Barbie Ganser-Pornillos, University of Virginia, Charlottesville, VA
4. The Capsid Inhibitor GS-6207 – Tomas Cihlar, Gilead Sciences, Foster City, CA, USA

Innate Immune Defenses Against HIV-1 and SARS-CoV-2 

1. Origin, Pathogenicity, and Immune Evasion Strategies of Human Coronaviruses – Volker Thiel, University of Bern, Bern, Switzerland
2. Immune Evasion of SARS-CoV-2: Nsp1 and Beyond – Konstantin Sparrer, Ulm University, Ulm, Germany
3. Restriction Factors: Shared Vulnerabilities and Different Countermeasures of HIV and SARS-CoV-2 – Eric Freed, National Cancer Institute, Frederick, MD, USA
4. Innate Responses to SARS-CoV2 and IFN Therapy – Akiko Iwasaki, Yale University, New Haven, CT, USA

Tuberculosis: New Approaches to Prevention and Treatment and Issues for Pregnant Individuals and Children

1. Long-Acting Injectables – Eric Nuermberger, Johns Hopkins University, Baltimore, MD, USA
2. Pregnant Women and HIV and Tuberculosis – Jyoti Mathad, Cornell University, New York, NY, USA
3. Children: HIV and Tuberculosis – Nicole Salazar-Austin, Johns Hopkins University, Baltimore, MD, USA
4. COVID, HIV, and Tuberculosis – Souyma Swaminathan, World Health Organization, Geneva, Switzerland

Effect of HIV on COVID, Effect of COVID on HIV

1. Does HIV Impact COVID-19 Susceptibility or Severity? Julia del Amo, Ministry of Health, Madrid, Spain
2. Effect of COVID-19 on Non-HIV Health Systems – Helen Bygrave, International AIDS Society, Geneva, Switzerland
3. Effect of COVID-19 on the HIV Pandemic Worldwide Andrew Kambugu, Infectious Diseases Institute-Makerere University, Kampala, Uganda
4. Effect of COVID-19 on HIV: Experiences on the Ground – Francois Venter, Wits Reproductive Health & HIV Institute, Johannesburg, South Africa

Opening

Welcome and Daily Roadmap

Plenary Presentations

Immunotherapy for HIV and COVID-19
Marina Caskey, Rockefeller University, New York, NY, USA

Sustained Delivery and Long-Acting Agents for Prevention of HIV
Linda-Gail Bekker, University of Cape Town, Cape Town, South Africa

Break

Concurrent Oral Abstract Sessions

New abstract-driven research in HIV infection, other emerging viral infections such as hepatitis C virus, and SARS-CoV-2.

Break

Concurrent Interactive Sessions

Interactive and scientifically fun sessions in a mixture of lively formats such as debates, point-counterpoint discussions, brief talks with expert panel discussions, and “Rapid Fire” sessions: 4 or 5 short (5 mins) presentations by experts in the field.

HIV-1 and SARS-CoV-2: Durability of Host Immune Responses from Vaccination or Infection

1. Waning Immunity in SARS-CoV-2 Infected Populations – Andrés Finzi, University of Montreal, Montreal, Canada
2. T Cell Immunity in SARS-CoV-2 (Vaccines vs Infection) – Julie McElrath, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3. Population-Level Immunity – Katie Doores, King’s College London, London, United Kingdom
4. Programming Durable Immunity – Robert Seder, Vaccine Research Center, Bethesda, MD USA
5. Pathological B cell activation during SARS-CoV-2 Infection – Ignacio Sanz, Emory University, Atlanta, GA, USA

From Daily Pills to Monthly Shots for HIV Prevention and Treatment: Can Efficacy Be Translated into Effectiveness?

• Moderators
  • Carlos del Rio, Emory University, Atlanta, GA, USA
  • Diane Havlir, University of California San Francisco, San Francisco, CA, USA
• Panelists
  • Francois Venter, Ezintsha School of Clinical Medicine, Johannesburg, South Africa
  • Nittaya Phanuphak, Institute of HIV Research and Innovation, Bangkok, Thailand
  • Charles Flexner, The Johns Hopkins University, Baltimore, MD, USA
  • Hyman Scott, San Francisco Department of Public Health, San Francisco, CA. USA

PrEP Scale-Up to Meet UNAIDS 2030 Goals: Is it Possible?

• Moderator: Sheena McCormack, University College London, London, United Kingdom
• Panelists
  • Elizabeth Irungu, Jomo Kenyatta University of Agriculture and Technology, Juja, Kenya
  • Mark Dybul, Georgetown University, Washington, DC, USA

Live Content Wrap-Up

Daily wrap-up of live content and a roadmap of on-demand content.

Science Spotlights^™

Science Spotlights^™ are a new format for presenting important science that is not part of an oral abstract session. More details are available on the Science Spotlights^™ page

Symposia

Two-hour Symposia include 4 state-of-the-art talks. Symposia are scheduled on each day of CROI. Speakers are provided 20 to 23 minutes to present.

Immune-Mediating Killing of HIV Reservoirs: Opportunities and Obstacles

1. Intrinsic Resistance of Reservoir Cells to Immune Killing – R. Brad Jones, Weill Cornell Medicine, New York, NY, USA
2. How to Generate Good Killers by Initiating ART (Not Too) Early? – Lydie Trautmann, Oregon Health Sciences University, Portland, OR, USA
3. Breaking the Germinal Center Barrier to Eliminate Viral Reservoirs – Afam Okoye, Oregon Health Sciences University, Portland, OR, USA
4. Interferon Resistance of Rebound HIV-1 – Beatrice Hahn, University of Pennsylvania, Philadelphia, PA, USA

Novel Antiviral Strategies and How to Deploy Them

1. How to Use and Position Dual  Antiretroviral Regimens – Jose Arribas, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
2. Novel Antiretroviral Therapies in Clinical Development – Alexandra Calmy, University Hospital Geneva, Geneva, Switzerland
3. ARVs and ART for Newborns and Infants: A Last Frontier – Moherndren Archary, University of KwaZulu-Natal, Durban, South Africa
4. Beyond Remdesivir: New Antivirals for Treatment of SARS-CoV-2 – Davey Smith, University of California San Diego, San Diego, CA, USA

COVID-19: Far More Than Just the Lungs

1. COVID-19: The Endothelium Unleashed – Peter Carmeliet, University of Leuven, Leuven, Belgium
2. Body on Fire: Multisystem Inflammatory Syndrome in Children – Elizabeth Whittaker, Imperial College London, London, United Kingdom
3. Think About It: Neurologic Manifestations of COVID-19 – Benedict Michael, University of Liverpool, Liverpool United Kingdom
4. COVID-19: Concerns of the Heart – Valentina Puntmann, Goethe University, Frankfurt, Germany

What does PrEP Deliver?

1. Young Women: Adherence, Effect, and Retention – Thesla Palanee-Phillips, Wits Reproductive Health and HIV Institute, Johannes, South Africa
2. Challenges and Opportunities in Implementing PrEP in Key Populations – Gregorio Millett, amFAR, Washington, DC, USA
3. Models of Delivering PrEP in Africa:  Implementation Issues – Moses Kamya, Makerere University College of Health Sciences, Kampala, Uganda
4. Cost-Effectiveness of New Formulations and Injectable PrEP – TBD

Opening

Welcome and Daily Roadmap

Plenary Presentations

Profiling the Latent HIV-1 Reservoir
Xu Yu, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

HIV Treatment During Pregnancy
Shahin Lockman, Brigham and Women’s Hospital, Boston, MA, USA

Break

Concurrent Oral Abstract Sessions

New abstract-driven research in HIV infection, other emerging viral infections such as hepatitis C virus, and SARS-CoV-2.

Break

Concurrent Interactive Sessions

Interactive and scientifically fun sessions in a mixture of lively formats such as debates, point-counterpoint discussions, brief talks with expert panel discussions, and “Rapid Fire” sessions: 4 or 5 short (5 mins) presentations by experts in the field.

SARS-CoV-2 and the Host Immune Response: Good vs Bad Immunity

1. Interferon Responses – Benjamin tenOever, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2. Innate Immune Responses to SARS-CoV-2 – Catherine Blish, Stanford University School of Medicine, Stanford, CA, USA
3. Afucosylated IgG Responses and Severity in COVID-19 – Gestur Vidarsson, University of Amsterdam, Amsterdam, Netherlands
4. Humoral Immune Responses to SARS-CoV-2 (VirScan) – Julie Overbaugh, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
5. The Spectrum of T cell Responses to SARS-CoV-2 – Markus Buggert, Karolinska Institutet, Stockholm, Sweden

COVID-19 Clinical Controversies

• Moderator: Roy Gulick, Weill Cornell Medical College, New York, NY, USA
• Panelists
  • Karine Lacombe, Saint-Antoine Hospital, Paris, France
  • Paul Sax, Brigham and Women’s Hospital, Boston, MA, USA
  • Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
  • Zarir Udwadia, Hinduja Hospital and Medical Research Center, Mumbai, India

COVID Disparities: How Can They Help Move the Needle Forward?

1. Disparities in COVID-19 Among Racial and Ethnic Minorities in the USA – Mary Bassett, Harvard T.H. Chan School of Public Health, Boston, MA, USA
2. Disparities in COVID-19 in Native American Communities – David Wilson, National Institutes of Health, Bethesda, MD, USA
3. Incarceration and COVID-19 – Robert Fullilove, Columbia University Medical Center, New York, NY, USA

Live Content Wrap-Up

Daily wrap-up of live content and a roadmap of on-demand content.

Science Spotlights^™

Science Spotlights^™ are a new format for presenting important science that is not part of an oral abstract session. More details are available on the Science Spotlights^™ page

Symposia

Two-hour Symposia include 4 state-of-the-art talks. Symposia are scheduled on each day of CROI. Speakers are provided 20 to 23 minutes to present.

New Findings and Unsettled Controversies in Central Nervous System HIV Reservoirs

1. Novel Findings of Neuronal Modulation of HIV Expression in Microglia- Jonathan Karn, Case Western Reserve University, Cleveland, OH, USA
2. Role of CNS CD4 T Cells and Macrophages in Neuropathogenesis and Reservoirs – Vanessa Hirsch, National Institutes of Health, Bethesda, MD, USA
3. Impact of Myeloid Reservoirs in HIV Cure Trials – Lishomwa Ndhlovu, Weill Cornell Medicine, New York, NY, USA
4. Lessons from CNS HIV Escape and ATI for Understanding HIV Persistence in the CNS – Sarah Joseph, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Adolescents, Youth, and PrEP

1. PrEP During Pregnancy and Breastfeeding – John Kinuthia, University of Nairobi, Nairobi, Kenya
2. Implementing PrEP Among High-Risk Adolescents and Youth – Sybil Hosek, Stroger Hospital, Chicago, IL, USA
3. Decision-Making Behaviors that Drive Uptake and Adherence to PrEP – Claude Mellins, Columbia University, New York, NY, USA
4. Improving How we Market PrEP to Youth – Elzette Rousseau, University of Cape Town, Cape Town South Africa

HIV and the Liver

1. Progress and Challenges in Hepatitis C Elimination – Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA
2. Mechanisms and Treatments of Steatosis in HIV – Steve Grinspoon, Harvard Medical School, Boston, MA, USA
3. Harnessing Innate Immunity To Cure HBV – Ulrike Protzer, Technische Universität München, Munich, Germany
4. New Prospects for the Treatment of HBV- Heiner Wedemeyer, Hannover Medical School, Hannover, Germany

COVID-19 Vaccine: From Efficacy to Effectiveness

1. Challenges in COVID Vaccine Trials – Michelle Williams, Harvard T.H. Chan School of Public Health, Boston, MA, USA
2. Vaccine Policy and Roll-Out – Kathy Neuzil, University of Maryland, Baltimore, MD, USA
3. Global Distribution of the SARS-CoV-2 Vaccine – TBD
4. Vaccine Hesitancy – Saad Omer, Yale University, New Haven, CT, USA